Transmission of Annual Report for the Year Ended December 31, 2025

2025 Annual Report

Table of Contents

01 Vision and Mission 03 Our Core Values

04 History of Major Events 06 Geographical Presence

07 Ownership and Group Structure 08 Corporate Information

09 Organizational Chart

10 Established Pharmaceuticals

12 Nutrition

14 Core Diagnostics

16 Diabetes Care

18 Key Brands

22 Product Launches

24 Awards and Recognitions

26 Significant factors effecting the external environment and the organization's response

28 Objectives, Strategy and Resource Allocation Plans

30 Key resources and capabilities of the company which provides sustainable competitive advantage

31 SWOT Analysis

32 Risks and Opportunities 34 Key Risks & Opportunities

36 Sustainability and Corporate Social Responsibility

44 CEO's Message 46 Directors' Profiles

48 Corporate Governance

54 Salient Features of Terms of Reference of Board Committees

1. Board Committees Attendance

2. Gender Pay Gap Statement

3. Stakeholders Relationship and Engagement

4. Future Outlook

5. Review Report by the Chairman

6. Review Report by the Chairman (Urdu)

7. Directors' Report

73 Directors' Report (Urdu)

74 2024 Financial Report

Abbott Pakistan / 2025 Annual Report

Our Vision

To be the most admired healthcare company in Pakistan.

Our Mission

To deliver consistently superior products and services which contribute significantly to improve the quality of life of consumers.

1

Abbott Pakistan / 2025 Annual Report

2

Our Core Values

Abbott Pakistan / 2025 Annual Report

Our purpose as a business is clear: we help people live healthier, fuller lives through our life-changing products, solutions and technologies.

Four core values guide how we support this purpose every day.

3

Abbott Pakistan / 2025 Annual Report

History of Major Events

1900

The business is officially incorporated in Illinois as the Abbott Alkaloidal Company.

1915

The Abbott Alkaloidal Company's name is changed

to Abbott Laboratories.

1920

Dr. Abbott breaks ground for a new manufacturing facility in North Chicago, Illinois.

This location will serve as the Company's headquarters for more than 40 years.

1929

Abbott's stock is listed on the Chicago Stock Exchange.

1931

Abbott's first international affiliate is established in Montreal, Canada.

1982 2004

1973

The global Abbott Diagnostics Division is formed to bring together the Company's diagnostic products and services.

Ensure, Abbott's first adult medical nutritional supplement, is introduced.

Abbott is listed as a public limited company in Pakistan.

2001

Abbott acquires the pharmaceutical

business of BASF, including the global operations of Knoll Pharmaceuticals.

Vysis, Inc., a leading

genomic disease management company, is also acquired.

Abbott Diabetes Care is created with the acquisition of Thera Sense Inc.,

a leading blood glucose monitoring business. Abbott also acquires

EAS Inc., a leader in performance nutrition products.

4

Abbott Pakistan / 2025 Annual Report

1948

Abbott starts its operations in Pakistan, as a private marketing company.

1962

Abbott opens its first manufacturing

facility in Karachi, Pakistan.

1964

Abbott acquires M&R Dietetic Laboratories of Columbus, Ohio.

1965

Major operations are moved to Abbott Park, a 420-acre site

southwest of its North Chicago headquarters.

2010

Abbott acquires Solvay Pharmaceuticals,

the global pharmaceutical business of the Solvay Group and STARLIMS

Technologies.

2013

Abbott separates into two leading healthcare companies, a diversified medical products company under the Abbott name and a research based pharmaceutical company, named AbbVie.

2014

Abbott acquires the control of CFR Pharmaceutical

thereby establishing Abbott among top pharmaceutical companies in Latin America. Abbott also acquires control of Veropharm, a leading pharmaceutical manufacturer in Russia.

2017

Abbott acquires St. Jude Medical. The acquisition strengthens Abbott's presence in cardiovascular area, thus making Abbott a premier medical device Company. Abbott also acquires Alere,

a company focusing on cardiometabolic, infectious disease and toxicology testing.

5

Abbott Pakistan / 2025 Annual Report

Geographical Presence

UNITED STATES, LATIN AMERICA AND CANADA

Illinois - Abbott Park - Head Office

Argentina Brazil Canada Chile Colombia Costa Rica

Dominican Republic Ecuador

El Salvador Guatemala Mexico Peru Puerto Rico

Trinidad and Tobago Uruguay

Venezuela

EUROPE

Albania Armenia Austria Azerbaijan Belarus Belgium

Bosnia-Herzegovina Croatia

Czech Republic Denmark Estonia

Finland France Georgia Germany Greece Hungary Ireland Italy Kazakhstan Latvia Lithuania

Moldova Netherlands Norway Poland Portugal

Republic of Serbia Romania

Russian Federation Slovakia

Slovenia Spain Sweden Switzerland Turkey Ukraine

United Kingdom Uzbekistan

MIDDLE EAST AND AFRICA

Egypt Israel Lebanon

Saudi Arabia South Africa

United Arab Emirates

ASIA PACIFIC

Australia China Hong Kong India Indonesia Japan Malaysia

New Zealand Pakistan Philippines Singapore South Korea Taiwan Thailand Vietnam

6

Abbott Pakistan / 2025 Annual Report

Ownership and Group Structure

Abbott Laboratories (Pakistan) Limited is a public listed company that was incorporated in Pakistan in 1948 as a private marketing company. It gradually expanded its operations over the years and is currently one of the largest pharmaceutical companies in Pakistan, and has presently two state-of-the-art manufacturing facilities based in Karachi. The Company is listed at the Pakistan Stock Exchange with 77.9% of its shares being held by Abbott Asia Investments Limited, UK.

Globally, Abbott operates in more than 160 countries and the ultimate holding Company is Abbott Laboratories, USA which is head-quartered in Abbott Park, Chicago - Illinois.

Related parties with which the Company has had transactions during the year are disclosed in Note 34.4 of the financial statements.

ULTIMATE HOLDING COMPANY

Abbott Laboratories, USA

100%

Effective Shareholding

77.9%

Shareholding

Abbott Asia Investments Limited, UK

PARENT COMPANY

Abbott Laboratories (Pakistan) Limited

7

Abbott Pakistan / 2025 Annual Report

Corporate Information

BOARD OF DIRECTORS

Ehsan Ali Malik (Chairman) (Non-Executive Director)

Syed Anis Ahmed (Chief Executive Officer)

Celestino Jacinto Dos Anjos (Non-Executive Director)

Ayla Majid (Independent Director)

Mohsin Ali Nathani (Independent Director)

Brian William Jordan (Non-Executive Director)

Seema Khan (Executive Director)

AUDIT COMMITTEE

Mohsin Ali Nathani (Chairman) Ayla Majid

Celestino Jacinto Dos Anjos

HUMAN RESOURCE AND REMUNERATION COMMITTEE

Mohsin Ali Nathani (Chairman) Ehsan Ali Malik

Syed Anis Ahmed

RISK MANAGEMENT COMMITTEE

Ayla Majid (Chairperson) Syed Anis Ahmed Seema Khan

Celestino Jacinto Dos Anjos

SHARE TRANSFER COMMITTEE

Syed Anis Ahmed (Chairman) Celestino Jacinto Dos Anjos Seema Khan

BANKING COMMITTEE

Mohsin Ali Nathani (Chairman) Syed Anis Ahmed

Seema Khan

Celestino Jacinto Dos Anjos

NOMINATION COMMITTEE

Ehsan Ali Malik (Chairman) Mohsin Ali Nathani

Syed Anis Ahmed

CHIEF FINANCIAL OFFICER

Syed Tabish Aseem

COMPANY SECRETARY

Muhammad Usama Jamil

CHIEF INTERNAL AUDITOR

Muhammad Ali Shiwani

AUDITORS

EY Ford Rhodes, Chartered Accountants

(a member firm of Ernst & Young Global Limited)

LEGAL ADVISORS

Orr, Dignam & Co. Surridge & Beecheno

BANKERS

Standard Chartered Bank (Pakistan) Limited Deutsche Bank AG

Habib Bank Limited National Bank of Pakistan MCB Bank Limited

Faysal Bank Limited Habib Metropolitan Bank Citibank

SENIOR MANAGEMENT TEAM

Syed Anis Ahmed

(Chief Executive Officer) Syed Tabish Aseem (Chief Financial Officer) Moien Ahmed Khan (Director Operations)

Asim Shafiq

(General Manager, Abbott Nutrition International Pakistan)

Saad Siddique

(Country Manager, Abbott Diagnostics Division Pakistan)

Dr. Shaikh Adnan Lateef

(Head of Abbott Diabetes Care Pakistan)

Asghar Huda

(Director Human Resource)

SHARE REGISTRAR

FAMCO Share Registration Services (Pvt) Limited, 8-F, Next to Hotel Faran, Nursery Block 6, P.E.C.H.S, Shahrah-e-Faisal, Karachi.

FACTORY LOCATIONS

Plot No. 258 & 324, Opposite Radio Pakistan Transmission Centre, Hyderabad Road, Landhi, Karachi.

Plot No. 13, Sector 20,

Korangi Industrial Area, Karachi.

CITY OFFICE

11th and 12th Floors, Ocean Tower,

G-3, Block-9, Main Clifton Road, Karachi.

SALES OFFICES

House No. 25/III/B, Jamrud Lane, University Town, Peshawar, Pakistan.

WAREHOUSES

Plot No. 136, Street # 9, Sector 1-10/3, Industrial Area, Islamabad.

16 KM Shahpur Kanjran, Multan Road, Lahore.

Hasanabad Gate # 2, Near Pak Arab Fertilizers, Khanewal Road, Multan.

WEBSITE

https://www.pk.abbott

8

Organizational Chart

Abbott Pakistan / 2025 Annual Report

SHAREHOLDERS

BOARD OF DIRECTORS

RISK MANAGEMENT COMMITTEE

HUMAN RESOURCE & REMUNERATION COMMITTEE

NOMINATION COMMITTEE

SHARE TRANSFER COMMITTEE

AUDIT COMMITTEE

BANKING COMMITTEE

CHIEF EXECUTIVE OFFICER

INTERNAL AUDIT

MANAGEMENT

DIABETES CARE

ESTABLISHED PHARMACEUTICALS

CORPORATE FUNCTIONS

GENERAL HEALTHCARE

NUTRITION

CORPORATE HUMAN RESOURCE

DIAGNOSTICS

CORPORATE FINANCE SERVICES

OFFICE OF ETHICS & COMPLIANCE

9

Abbott Pakistan / 2025 Annual Report

Established Pharmaceuticals

Advancing Access to Trusted, High Quality Therapeutic and Preventive Healthcare Products.

Good health is fundamental to quality of life, yet it is often challenged by everyday ailment to more serious medical conditions. People rely on pharmaceutical products to support recovery and maintain their wellbeing. Around the world, millions depend on access to affordable, high quality pharmaceutical products that help them to lead healthier and more productive lives.

Abbott remains committed to broadening access to high quality, branded generic pharmaceuticals that meet the diverse health needs of the communities we serve. Our portfolio includes a wide range of treatment options across key therapeutic areas,

including digestive health, women's health, respiratory conditions, central nervous system and pain management, as well as influenza vaccines.

10

Abbott Pakistan / 2025 Annual Report

Broad Portfolio of more than 150SKUs

1

Product Launch

2

Manufacturing Facilities

Our long standing reputation for quality and reliability drives us to continuously improve our products and make them more effective, easier to administer and faster to act to deliver improved patient outcomes. We recognise that better care requires both innovation and value, and we therefore tailor our product offerings to address the specific health needs of different patient populations.

Guided by the belief that the most impactful health products are those that reach and benefit the greatest number of people, Abbott remains focused on expanding and optimising its product portfolio.

Through this commitment, we aim to make a meaningful, life changing difference to more people, in more places.

For years, I struggled with unexplained fatigue, weight gain, and mood swings. No matter how hard I tried, everyday life felt heavy and exhausting. When I was finally diagnosed with thyroyd disorder, everything started to make sense, though I was still worried about how I would get my life back.

My doctor prescribed Thyronorm to me, today I feel balanced, active, and genuinely at peace.

Thyronorm did not just treat my condition, it gave me back the life I had been missing.

Mrs. Lubna Waqar

Karachi, Pakistan

11

Abbott Pakistan / 2025 Annual Report

NUTRITION

Science-based nutrition to support the growth, health, and wellness of people at every stage of life.

Aileen is five. She is cheerful, curious, and full of questions. But just three months ago, she wasn't as active as her friends. Many days, her lunchbox

came back untouched, and she got tired quickly. A picky eater, she left her mother wondering if her growth might slow down at this important age.

During a visit to their pediatrician, her mother learned that low energy in growing years can be linked

to incomplete nutrition and was recommended PediaSure. With complete, balanced nutrition', including 37 vital nutrients, Arginine® and Vitamin K2ª, PediaSure supports bone and muscle developments with 50% faster growth.

In just 12 weeks, Aileen became more active than her friends, and her height began to visibly grow. She is now keeping up with her peers, and her mother feels more confident.

Aileen's Mother

Karachi, Pakistan.

12

Abbott Pakistan / 2025 Annual Report

®

NUTRITION FOR STRONGER TODAY

At age 50, I began to notice that I got tired more easily than before. Playing with my grandchildren left me out of breath, and even simple tasks felt more demanding. I realized that as I am aging, my muscle strength is naturally declining and staying active is getting difficult. My doctor recommended me complete & balanced nutritional support of Ensure.

Determined to maintain my mobility, I added Ensure to my daily routine for complete and balanced nutrition In 90 days, I experienced improved muscle strength and felt stronger and more energetic.

Today, I keep up with my grandchildren's laughter, games, and boundless energy, enjoying every moment without holding back.

Sajid Malik

Karachi, Pakistan.

13

Abbott Pakistan / 2025 Annual Report

CORE DIAGNOSTICS

Customised, scalable solutions improving throughput, accuracy, and productivity in diagnostic laboratories.

14

Abbott Pakistan / 2025 Annual Report

AlKhidmat Network - Powered by Abbott for Accurate & Reliable Diagnostics

The AlKhidmat Network operates under the umbrella of the Alkhidmat Foundation Pakistan, one of the country's largest non-profit healthcare systems.

With over 116 diagnostic laboratories and collection centers across Pakistan, the network is committed to delivering credible, affordable, and quality-assured diagnostic services to communities nationwide.

Nearly one year ago, Abbott Diagnostics entered a formal partnership with the AlKhidmat Network, further strengthening its diagnostic excellence

across multiple locations. Through this collaboration, Abbott's time-tested, state-of-the-art ARCHITECT Immunoassay and Clinical Chemistry systems have been deployed within the network. These advanced

Our partnership with Abbott, now approaching a year, has significantly elevated the quality of our diagnostic services. With Abbott's advanced immunoassay and clinical chemistry systems, we are delivering faster, and more precise results that enhance clinical decision-making.

Abbott's ongoing training and technical support continue to strengthen our team's capabilities, helping us maintain high standards of accuracy and efficiency. This collaboration is truly raising the bar for the services we provide.

Dr. Zeeshan Hussain

Associate Professor, Chief Pathologist AlKhidmat Diagnostics

instruments support timely, precise, and reliable testing, ensuring physicians receive actionable results for critical healthcare decisions.

Abbott has also extended comprehensive academic and training support, enabling AlKhidmat's technical teams across the network to pursue continuous professional development. This ensures staff competency, quality performance, and adherence to global diagnostic standards.

This partnership has enhanced operational efficiency, improved diagnostic accuracy, and contributed significantly to the Network's mission of delivering uncompromised quality and patient-centered diagnostic care throughout Pakistan.

The Abbott ARCHITECT family is a comprehensive suite of automated diagnostic analyzers designed for clinical chemistry, immunoassay, and integrated testing, focusing on laboratory efficiency, high throughput, and consolidated workflows.

These analyzers utilize standardized, intelligent technology for consistent patient results across small- to high-volume labs.

Excellent STAT turnaround time

Ease of use

Improved workflow

Confidence in results

Reduced costs

15

Abbott Pakistan / 2025 Annual Report

DIABETES CARE

Transforming diabetes management to be easier, smarter, and more accessible.

16

Abbott Pakistan / 2025 Annual Report

Abbott's world leading FreeStyle Libre portfolio of continuous glucose monitors has revolutionized the way nearly 6 million people worldwide manage their diabetes. Our commitment to innovation has

established Abbott as the global leader in continuous glucose monitoring.

Abbott Diabetes Care operates on a unique direct to customer business model for its flagship brand, the FreeStyle Libre system. FreeStyle Libre system has been named the Best Medical Technology of the Last 50 Years by the Galien Foundation.

FreeStyle Libre system consists of two components, FreeStyle Libre Reader and FreeStyle Libre Sensor. Together, they enable people with diabetes to continuously monitor their glucose levels, giving them access to meaningful data that supports better decision making and helps improve overall quality of life.

The Experience Centers offer a unique opportunity to visit a site designed and developed exclusively for educating visitors about the FreeStyle Libre system. These centers are staffed with trained Diabetes Educators who guide patients and their caregivers on

the application, care, usage, and data interpretation of the FreeStyle Libre system.

Additionally, when an order is placed through the website or call center, FreeStyle Libre system is delivered free of cost to the purchaser's doorstep. This service also includes a complimentary visit from one of our resident Diabetes Educators.

At selected pharmacies where the FreeStyle Libre system is available, trained pharmacists are present. They have been educated on how to apply, use, care for, and help patients get the most out of the FreeStyle Libre system.

My son, Murad Naveed, was 8 years old when his doctor recommended the FreeStyle Libre system for him. Before

using this device, life was quite hectic and difficult. Checking his glucose manually by pricking his fingers 6 to 7 times a day was extremely painful for him and even more difficult for me as a parent watching him go through that pain.

Thanks to the FreeStyle Libre system, life has become much easier and stress free. I can now check my son's glucose levels anytime and anywhere without any hassle. I have been using this device for him since 2023, and I am happy to share that Murad's HbA1c has reduced from 8-9% to 6-7%.

It has been especially helpful at night, as I don't have to wake him up to check his glucose levels. Overall, my experience with the FreeStyle Libre System has been excellent

Ana Naveed

Murad's Mother

17

Abbott Pakistan / 2025 Annual Report

Key Brands

Brufen is Abbott Pakistan's flagship and highest volume selling brand with sales of 94.2 million* Units per annum. Due to its high HCP acceptance and strong brand equity, Brufen approximately generates 68,099** prescriptions per day. In 2025, the brand not only maintained its volume leadership position but also achieved a major milestone of achieving a value of PKR 10.5 billion*. Through continuous day-to-day HCP and Trade engagements the brand continued to increase its share of voice.

* IQVIA Audit, Pharmaceutical Index of Pakistan PKPI - MAT 12 2025

** IQVIA MIP Plus S2 2025

Surbex Z is the no. 1 brand on value, volume* and prescription** in the Vitamin B complex market. It is also the # 1 prescribed brand in the vitamins market with

21.4 million annual prescriptions**. Surbex Z is a legacy brand for Abbott with a 29-year history of efficacy and trust. Millions of consumers across the country have been benefited from the advantages of Surbex Z at some point in life. The brand engaged HCPs through its creative and innovative campaigns using scientific material and digital tools of engagement throughout the year 2025. Our well known disease awareness campaign has helped us raise awareness regarding Zinc deficiency through multiple channels across the nation. We continue to serve our patients and improve their lives by delivering quality with affordability.

* IQVIA MAT Dec 2025

** IQVIA MIP MAT Dec 2025

18

Abbott Pakistan / 2025 Annual Report

Duphaston is the World's no. 1 Brand* in with a versatile Progestogen "Dydrogesterone" for women suffering from progesterone deficient disorders. Duphaston is leading the progesterone market by having 56% value market share and has crossed milestone of PKR 5.7 billion as per IQVIA MAT December 2025. Duphaston is highly selective for progesterone receptors, making it a convenient

orally effective luteal phase support. It is experienced in more than 113 million women and more than 20 million pregnancies in more than 100 countries worldwide.

* MAT09 2025 product letter_Q3 2025

Arinac is Pakistan's no.1* cough and cold brand in value and continues to be the market leader and the preferred choice among healthcare professionals. The product's success is further

supported by strong brand recognition resulting in achieving the milestone of PKR 5 billion* in 2025 and solidifying its position as the top choice in the market.

* IQVIA MAT December 2025

19

Abbott Pakistan / 2025 Annual Report

Key Brands

Ensure is science-based, complete & balanced, no. 1 nutritional supplement drink in the world, which aspires for healthy adults aged 50+ who are beginning to feel the signs of aging (physical and mental) and are motivated to make lifestyle changes by including specialized nutrition to better manage their aging process. The brand has been serving the nutritional needs of Pakistanis since 1990. Key areas of focus for Ensure include healthy aging, fast recovery of hospitalized and surgery patients, as well as those who are critically ill and have additional nutritional needs. Ensure is clinically proven to improve muscle strength in 90 days.

Pediasure is a scientifically designed complete and balanced nutritional supplement for children aged 3-10 years. It aims to be the leading nutrition solution partner of mothers concerned about their child's eating habits and its impact on their growth. Pediasure's new and improved formula with TripleSure System contains 37 essential nutrients, Arginine and Vitamin K2 that helps children overcome nutritional deficiencies and improve their height, weight & immunity and achieve 50% faster growth.

Glucerna is the no. 1 selling diabetes nutrition drink in the world which is scientifically-formulated to fulfil specific nutritional needs of people with pre-diabetes and diabetes. Its unique Triple Care system makes Glucerna an integral component of patients' diabetes management plans, by helping them improve their quality of life through optimization of key cardiometabolic indicators Glucerna helps manage glucose levels in 4 weeks by reducing body weight

by upto 4%, Fasting Blood glucose by upto 14% and current Hba1c levels by upto 11%.

20

Abbott Pakistan / 2025 Annual Report

The FreeStyle Libre 2 Flash Glucose Monitoring System ("Sensor") when used with a compatible device FreeStyle Libre 2 Flash Glucose Monitoring System ("Reader") is indicated for measuring interstitial fluid glucose levels in people (age 4 and older) with diabetes mellitus, including pregnant women. The Sensor and compatible device are designed to replace blood glucose testing in the self-management of diabetes, including dosing of insulin.

Our sensing technology - the FreeStyle Libre 2 System -gives users data and insights conveniently and in an easily

understandable way. The sensor, worn on the back of the upper arm, automatically tracks glucose levels - every minute, day and night. FreeStyle Libre 2 users can get a glucose reading, plus record the trends in their levels, giving them the confidence

to make the right decisions because they know how different foods, exercise and medications impact their health.

Abbott's STAT High Sensitive Troponin I (hsTnI) assay enables early and accurate identification of individuals at elevated risk of future cardiac events, including heart failure, myocardial infarction, and ischemic stroke. As a cardiac specific biomarker, hsTnI supports more precise

risk classification in asymptomatic individuals, enhancing clinicians' ability to proactively tailor care and mitigate adverse outcomes. The assay's high analytical sensitivity allows detection of even low level myocardial injury, enabling early cardiac risk stratification and empowering long term preventive interventions.

Integrated into Abbott's Alinity i and ARCHITECT platforms, the hsTnI assay delivers consistent performance that supports individualized care pathways and reduces unnecessary investigations. By enabling earlier identification of at risk patients, the hsTnI assay plays a vital role in improving cardiovascular outcomes and advancing proactive, preventive healthcare laboratories run at their best, today and into the future.

21

Abbott Pakistan / 2025 Annual Report

Product Launches

New product development is a driving force for organizational growth and an essential component of sustainable progress. At Abbott, we remain committed to delivering innovative solutions that address enduring health challenges and enable people to live fuller, healthier lives. Abbott Pakistan continues to champion this commitment by closely monitoring evolving market needs and consistently introducing differentiated products and solutions to meet the expanding demands of the domestic healthcare landscape.

Brufen IV 400mg/4ml Ampoules

Continuing to expand its legacy in pain and fever management, Abbott introduced its first ibuprofen in injectable form by the name of Brufen IV. This latest addition to the Brufen family offers safe and effective relief for hospitalized patients and emergency patients suffering from fever and moderate-to-severe pain.

Ensure 200g (Bag in a box)

In August 2025, Abbott Nutrition introduced the new 200g soft pack (vanilla flavour) for Ensure. This pack was designed to help Aging Adults who are feeling the toll of aging but would like to stay fit and active. For first time trial and taste this 200g Ensure soft pack is an ideal option before they move up the purchase ladder and upgrade to bigger size 400g and 850g tins.

To support the launch, visibility and availability of the new pack have been ensured across all major channels, including pharmacies, retail outlets, key accounts, and e-commerce platforms.

22

Abbott Pakistan / 2025 Annual Report

PediaSure 600g (Bag in a box)

In September 2025, Abbott Nutrition introduced the new 600g Pediasure soft pack in vanilla flavour. This pack is designed to help loyal 400g users transition more easily to a larger size, especially those who found it challenging to upgrade directly to the 850g tin. The 600g soft pack offers superior value for money on a per-gram basis compared to the tin format.

To support the launch, visibility and availability of the new pack have been ensured across all major channels, including pharmacies, retail outlets, key accounts, and e-commerce platforms

Abbott's GLP Systems Track is an innovative total laboratory automation solution designed to deliver enhanced flexibility, scalable configurations, and proven technology to support high volume diagnostic operations.

The system's modular, customizable track architecture allows laboratories to adapt layouts effortlessly, optimize workflows, and maintain uninterrupted operations, even as testing demand evolves. Featuring intelligent CAR self propelled sample carrier technology, GLP Systems Track increases operational continuity by preventing systemwide downtime and enabling independent sample movement for superior performance.

With significant reductions in manual steps and mechanical failures, the GLP Systems Track enhances productivity, improves safety, and accelerates turnaround times, helping laboratories meet growing clinical needs efficiently. Built for the future of diagnostics, GLP Systems Track empowers laboratories with smarter automation, optimized sample management, and a robust, high performance workflow framework.

23

Abbott Pakistan / 2025 Annual Report

Awards and Recognitions

Over the past year, our steadfast commitment to excellence and innovation has been recognized through several prestigious awards. These honors reflect the dedication, hard work, and high standards upheld by our teams as they continually strive for outstanding results. We are privileged to receive acknowledgment for our contributions to the industry and the community. Each accolade not only celebrates our achievements but also motivates us to pursue even greater milestones as we advance on our journey towards excellence.

These recognitions reaffirm our strategic direction and reinforce our belief in the value we create for our stakeholders. They underscore the strength of our culture, the resilience of our people, and our unwavering focus on driving sustainable impact. As we continue to invest in our capabilities, embrace innovation, and elevate operational excellence, we remain committed to setting new benchmarks and delivering meaningful progress for the patients, partners, and communities we serve.

Abbott Pakistan Secures First Place at the 40th Corporate Excellence Awards

Abbott Pakistan received the First Prize from the Management Association of Pakistan (MAP) in the pharmaceutical sector. The Corporate Excellence Awards, organized annually by MAP, recognizes the best-managed companies in the Country that demonstrate exemplary management practices, adopt modern techniques, and uphold principles that drive continuous improvement and innovation. MAP's rigorous evaluation process includes a comprehensive assessment of management

practices through detailed questionnaires and leadership discussions, as well as an in-depth financial review based on the companies' annual reports.

24

Abbott Pakistan / 2025 Annual Report

Alliance for Water Stewardship (AWS) Certification - 2025

In 2025, Abbott achieved the Alliance for Water Stewardship (AWS) Certification after a rigorous external audit. This globally recognized certification reflects Abbott's strong commitment to responsible water management, sustainable water practices, and long-term environmental stewardship.

Water Stewardship Management Award - OICCI Climate Excellence Award 2025

Abbott Pakistan received the 1st Climate Excellence Award in Water Stewardship at the 3rd Pakistan Climate Conference 2025, organized by the Overseas Investors Chamber of Commerce & Industry (OICCI).

This recognition highlights Abbott's commitment to responsible water management, conservation, and sustainable manufacturing practices, including reducing freshwater consumption and improving water reuse at its facilities.

Corporate Social Responsibility Awards - NFEH

Abbott Pakistan received the Corporate Social Responsibility Award at the 17th NFEH CSR Awards, recognizing its contributions to community development, healthcare access, education initiatives, and employee-driven volunteering efforts. The award highlights Abbott's commitment to improving lives and supporting sustainable community development

22nd Annual Environmental Excellence Award - NFEH

Abbott Pakistan received the 22nd Annual Environmental Excellence Award from the National Forum for Environment & Health (NFEH). The recognition highlights Abbott's strong commitment to environmental sustainability, regulatory compliance, and the implementation of responsible and efficient operational practices.

25

Abbott Pakistan / 2025 Annual Report

Significant factors affecting the external environment and the organisation's response

P

POLITICAL

Political uncertainty and inconsistent policies

ORGANISATIONAL RESPONSE

• Discussion and engagement with relevant

authorities on future policies and measures

• Industry issues are dealt through Pharma Bureau and other business associations

E

ECONOMIC

Increasing labour costs, fluctuating interest rates, inflation, low economic growth and exchange rate fluctuations impact profitability.

ORGANISATIONAL RESPONSE

• Reduce costs through cost-containment initiatives

  • Price adjustments

S

SOCIAL

Corporate Social Responsibility (CSR), increasing attention in healthcare, charity and donation, safe and healthy environment.

ORGANISATIONAL RESPONSE

• Active participation in social work initiatives as

part of CSR

26

Abbott Pakistan / 2025 Annual Report

T

TECHNOLOGICAL

Technological obsolescence, competitors capitalising on new opportunities created by technological advancements.

ORGANISATIONAL RESPONSE

• Actively invest in different projects to improve efficiency,

build capacity and achieve operational excellence

L

LEGAL

Drug Regulatory Authority of Pakistan Act, 2012, Companies Act, 2017, Income Tax Ordinance 2001, Sales Tax Act, 1990, PSX Rulebook, SECP Act, 1997 and others.

ORGANISATIONAL RESPONSE

• The Company ensures compliance with all the

applicable laws and regulations. The Company's Finance, Compliance, Medical, and Regulatory departments monitor any new legislations impacting the Company and ensures compliance

E

ENVIRONMENTAL

Growing attention to environmental protection, climate changes, natural disasters and natural resource conservation.

ORGANISATIONAL RESPONSE

• The Company complies with Abbott Global Standards

  and local environmental requirements, supported by its Zero Waste to Landfill Certification.

• The recent recognitions for reducing freshwater

consumption and improving water reuse further reflect the Company's commitment to broader sustainability practices.

27

Abbott Pakistan / 2025 Annual Report

Objectives, Strategy and Resource Allocation Plans

28

Abbott Pakistan / 2025 Annual Report

29

Abbott Pakistan / 2025 Annual Report

Key resources and capabilities of the Company which provides sustainable competitive advantage

Trust - a brand that is trusted by healthcare professional and patients alike

Two State-of-the-art Manufacturing Facilities - help ensure operational excellence & products availability

Diversified Business Segments - helps us remain insulated from volatility in any one market

Over 1,300 Employees - High-performance culture, driven to succeed

Product Portfolio - Our patient centric products offering, aligned with key health trends

30

SWOT Analysis

Abbott Pakistan / 2025 Annual Report

Strengths Weaknesses Opportunities Threats

• Dependence on imported raw materials

• Regulated prices on pharmaceutical products

• Great potential in the export and local market to capture new markets and grow consumer base through an added advantage of diversified product portfolio

  • Frequent changes in government policies

  • Inconsistent fiscal policies

  • Political instability

  • Deteriorating exchange rates & inflation

  • Counterfeit Products

  • Intense competition prevailing in the industry

• New product innovations and additional variants can grow and diversify the portfolio

• Leveraging new digital technology for the benefit of patients

• Increasing population coupled with increasing awareness and focus towards healthcare

• Capitalizing on health care programs or schemes initiated by the Government

31

Risk Management Framework

As a leading pharmaceutical company, Abbott operates in a highly regulated and competitive environment, where effective risk management is essential for safeguarding stakeholder value and ensuring sustainable performance. Abbott maintains a structured Enterprise Risk Management (ERM) framework that

is fully integrated with its strategic planning, financial oversight, and operational processes. The framework enables systematic identification, evaluation, and mitigation of risks that may affect the company's strategic objectives, financial position, operational continuity, and reputation. Risk assessments are conducted periodically by management in coordination with the Internal Audit function. Identified risks are evaluat-

ed based on their likelihood and potential impact, and are assigned to responsible functional heads for monitoring and mitigation. Control measures include strengthening internal controls, updating Standard Operating Procedures, enhancing compliance monitoring, and improving operational processes. Over-

sight is exercised by the Risk Management Committee and the Audit Committee, while the Board of Directors retains ultimate responsibility for risk governance

and determination of risk appetite. This structured

approach ensures accountability, transparency, and a timely response to emerging risks.

Assessment of Principal Risks and Uncertainties

In 2025, Abbott continues to operate in an environment influenced by regulatory developments, evolving market conditions, and significant climatic disruptions. Geopolitical volatility is likely to contribute to broader macroeconomic instability, which may give rise to inflationary pressures, exchange rate fluctuations, and shifts in consumer demand. These dynamics could impact cost structures and margins, particularly in relation to imported raw materials and distribution expenses. Abbott manages these exposures through disciplined financial planning, prudent treasury management, and cost optimization initiatives.

Given the nature of the pharmaceutical industry, regulatory and compliance risks remain significant. Changes in taxation, pricing regulations, product registration requirements, and quality standards may affect operational timelines and profitability. Abbott maintains robust compliance systems, periodic internal reviews, and strict adherence to regulatory standards to mitigate these risks.

32

Abbott Pakistan / 2025 Annual Report

Risks and Opportunities

Board Oversight and Risk Appetite

The Board of Directors of Abbott is responsible for reviewing principal risks and ensuring that they are managed within defined tolerance levels. Through regular reporting and committee oversight, the Board evaluates the effectiveness of mitigation strategies and confirms that appropriate internal control systems are in place. Based on its review, the Board is satisfied that Abbott's risk management framework remains effective and aligned with the company's strategic objectives.

Opportunities

Despite prevailing uncertainties, Abbott recognizes opportunities arising from growth in the pharmaceutical sector, evolving patient needs, and operational efficiencies. Strategic focus on product portfolio strengthening, market penetration, process optimization, and responsible business practices positions Abbott to enhance competitiveness and sustain long-term value creation. By maintaining a balanced approach to risk and opportunity management, Abbott remains committed to protecting stakeholder interests while pursuing disciplined growth in 2025 and beyond.

33

Abbott Pakistan / 2025 Annual Report

Abbott Pakistan / 2025 Annual Report

Key Risks & Opportunities

34

Abbott Pakistan / 2025 Annual Report

35

Abbott Pakistan / 2025 Annual Report

Sustainability and Corporate Social Responsibility

Abbott has been operating in Pakistan for more than 78 years, advancing its purpose of enabling people to live fuller, healthier lives through life-changing technologies and products. We believe that a sustainable future begins with health, as good health underpins social mobility, economic productivity, and resilient communities. Guided by Abbott's 2030 Sustainability Plan, our CSR strategy prioritizes expanding access and affordability, while

removing systemic barriers that prevent underserved populations from receiving timely, high-quality healthcare. Our community investments focus on healthcare access, disability inclusion, maternal

and child health, chronic disease management, and education - aligning our business strengths with societal needs to deliver measurable and sustainable impact.

Abbott's vision for the future of healthcare is grounded in building and sustaining people's health by advancing a comprehensive healthcare system-one that moves beyond the traditional, treatment focused "sick care" model. We are developing innovative products and solutions that empower individuals with greater knowledge and control over their health, enabling them to better understand their bodies and respond proactively. Our key focus areas are outlined below:

IMPROVING ACCESS AND AFFORDABILITY

Abbott's product design, development, manufacturing, and commercialization processes are guided by a robust set of design principles that aim to expand access and promote equity:

Design for Broader Reach and Equity

Develop an innovative portfolio that reaches more people, including underserved populations, new geographies, and communities with limited access to healthcare.

Design for Access

Identify and address barriers to access and adoption through inclusive design, as well as optimized manufacturing, distribution, and technology strategies across the value chain.

Design to Optimize Reach and Value

Make deliberate, data-driven decisions throughout the design process to maximize four critical factors: the number of people reached, consumer benefit, business value, and societal impact.

Transforming Care

Advancing disease-management solutions is central to improving healthcare quality. In addition to enhancing capabilities in disease detection and prevention, Abbott actively supports global efforts to address non-communicable diseases, including diabetes and cardiovascular conditions, which

continue to pose significant public health challenges worldwide.

Advancing Health Equity

Abbott's health-equity initiatives leverage its core strengths as a healthcare innovator by fostering partnerships and supporting communities to enable healthier lives. These efforts focus on improving care coordination, addressing social drivers of health, and strengthening local capacity.

During the year, Abbott Pakistan collaborated with leading nonprofit organizations to expand access to essential healthcare, education, and social services, contributing to the development of healthier and more resilient communities.

BUILDING THE DIVERSE, INNOVATIVE WORKFORCE OF TOMORROW

Abbott is deeply committed to its purpose of helping people live healthier, fuller lives. Across all roles and functions, employees recognize that their work has a meaningful and lasting impact on the lives of those we serve.

36

Abbott Pakistan / 2025 Annual Report

We depend on the innovation, dedication, and lived experiences of a diverse workforce to deliver sustainable solutions. Abbott strives to be an

employer of choice, offering purposeful work within a global community united by a shared mission. Our talent-management strategy emphasizes attracting,

retaining, engaging, and developing a diverse and high performing workforce.

Talent Acquisition

Our talent-acquisition strategy focuses on building a robust and diverse talent pipeline through early career programs, diversity-focused recruitment initiatives, and the hiring of top talent to support long-term organizational success.

Diversity, Equity, and Inclusion

Abbott is committed to fostering an inclusive workplace that promotes diversity, equity, and inclusion (DEI). This commitment strengthens our business, fuels innovation, and supports greater collaboration. We continuously work to cultivate a culture in which every employee feels respected,

valued, and empowered to bring their authentic selves to work.

Employee Development

Abbott provides a broad range of learning and development opportunities, including mentoring programs, leadership-development initiatives, and personalized career-planning tools. These resources are available at every stage of an employee's career and are designed to support continuous growth and professional advancement.

Employee Well-Being, Health, and Safety

Abbott encourages employees to prioritize their physical, emotional, and mental well being by offering a comprehensive suite of benefits and support services. The health and safety of employees and contractors remain a core priority and non-negotiable standard. We promote safe behaviors through targeted communications and a robust measurement system that monitors performance and behavioral observations.

PROTECTING A HEALTHY ENVIRONMENT

Abbott depends on natural resources to manufacture and deliver products that improve lives. We are committed to using these resources responsibly

to protect the environment for current and future generations.

Energy and Emissions

Reducing climate impact is essential to sustaining a healthy planet. Abbott is progressing toward near-term, science-based targets for carbon-emissions reduction through investments in renewable energy, improvements in manufacturing efficiency, and collaboration with suppliers. During the year, solar panels were installed at the manufacturing facility as part of these efforts.

37

Abbott Pakistan / 2025 Annual Report

Protecting Water Resources

Abbott successfully completed a desktop pre-assessment for Alliance for Water Stewardship (AWS) certification. This assessment evaluated site readiness for formal certification by reviewing water-management practices, policies, and procedures, and assessing alignment with AWS core principles,

including sustainable water balance and water quality management.

Abbott also marked World Water Day under the theme "Water for Peace", focusing on awareness-building and the exploration of water-conservation initiatives.

QUALITY MANAGEMENT

Abbott designs and delivers products and services with the same care and rigor as if they were intended for its own families. Continuous improvement of systems and processes is fundamental to ensuring the safety, effectiveness, and quality of our products.

Quality is embedded across the organization through Abbott's Quality Management System (QMS), which is continually reviewed to monitor performance, implement best practices, and proactively address industry specific challenges.

CREATING A RESILIENT, DIVERSE, AND RESPONSIBLE SUPPLY CHAIN

Abbott is committed to strengthening the sustainability and resilience of its supply chain while generating positive social and environmental impact. We uphold principles of environmental stewardship, human rights, and fair labour practices to support long-term business success.

Through partnerships with strategic suppliers, Abbott advances shared sustainability priorities, including responsible sourcing, supplier diversity, and continuity of supply. These collaborations drive collective action on human rights, labour standards, and environmental responsibility across the value chain.

Expanding Access to Critical Healthcare

Abbott Pakistan continues to collaborate with credible nonprofit institutions to improve access to high quality medical care for financially vulnerable populations.

Family Education Services Foundation (FESF)

Family Educational Services Foundation (FESF) is committed to empowering disadvantaged deaf

children and youth through inclusive education, skills development, job placement, and sign-language advancement.

Abbott's sustained contributions have supported the establishment and strengthening of higher- education programs in Sindh, promoting long-term educational and economic empowerment of hearing-impaired individuals.

Patients' Behbud Society for AKUH (PBS)

Patients' Behbud Society for AKUH (PBS) provides financial assistance to underprivileged patients seeking treatment at Aga Khan University Hospital.

In 2025, Abbott's funding supported pediatric patients suffering from complex and life threatening conditions, enabling access to high quality medical care that would otherwise remain inaccessible due to financial constraints.

38